新辅助免疫疗法开创胃癌治疗新时代
[Neoadjuvant immunotherapy ushers in a new era of gastric cancer treatment].
作者信息
Ji K, Zhou K, Gao X Y, Bu Z D, Ji J F
机构信息
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing 100142, China.
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing 100142, China.
出版信息
Zhonghua Wei Chang Wai Ke Za Zhi. 2024 Jul 25;27(7):653-658. doi: 10.3760/cma.j.cn441530-20240415-00137.
Recent advances in tumor immunology have made immunotherapy a new direction for neoadjuvant treatment of gastric cancer. Multiple clinical trials have confirmed that combining immunotherapy with chemotherapy and targeted therapy in the neoadjuvant treatment of gastric cancer can effectively improve treatment response and prolong patient survival time. This article aims to comment on the application of immunotherapy in the neoadjuvant treatment of gastric cancer, exploring its mechanisms, integration strategies with traditional treatments, safety, and personalized precision therapy in the hope of providing new insights and directions for the field of gastric cancer treatment.
肿瘤免疫学的最新进展使免疫疗法成为胃癌新辅助治疗的一个新方向。多项临床试验证实，在胃癌新辅助治疗中将免疫疗法与化疗和靶向治疗相结合可有效改善治疗反应并延长患者生存时间。本文旨在对免疫疗法在胃癌新辅助治疗中的应用进行评述，探讨其作用机制、与传统治疗的联合策略、安全性以及个性化精准治疗，以期为胃癌治疗领域提供新的见解和方向。
Zotero 插件